Page 6 - Fast Track Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 2 Trial Evaluates Annamycin Plus Ara-C In AML

A new Phase 1B/2 trial treated patients with acute myeloid leukemia (AML) in a drug regimen combination of Annamycin and Ara-C.

Walter klempDrug administrationNational institutes of healthMoleculin biotechUsing annamycinNational institutesMoluclin biotechFast track statusOrphan drug designationAcute myeloid leukemia

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML HOUSTON, Oct..

United statesJenene thomasWalter klempSecurities exchangeMoleculin biotech incDrug administrationCompany phaseExchange commissionFast track statusOrphan drug designationMoleculin biotechChief executive officerTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform act

Moleculin Announces Completion of Enrollment in U S Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including.

United statesJenene thomasWalter klempExchange commissionEastern cooperative oncology groupPrnewswire moleculin biotech incSecurities exchangeCompany us phaseConnective tissue oncology society annual meetingDrug administrationMoleculin biotech incFast track statusOrphan drug designationChief executive officerConnective tissue oncology societyAnnual meeting

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML.

United kingdomUnited statesTacaribe arenavirusJenene thomasLiposomal annamycinWalter klempEuropean unionBritish journal of cancer researchNational institutes of healthMoleculin biotech incDrug administrationExchange commissionSecurities exchangeCompany core technologiesNorthwestern universityMoleculin biotech

Moleculin Biotech (MBRX) Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

Moleculin Biotech (MBRX) Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomWalter klempTacaribe arenavirusLiposomal annamycinCompany core technologiesBritish journal of cancer researchNational institutes of healthEuropean unionDrug administrationMoleculin biotech incNorthwestern universityMoleculin biotechChief executive officerGeneration anthracyclineRecommended phaseAfter induction therapy